Cargando…

A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world

BACKGROUND: Roflumilast is approved in the United States to reduce the risk of COPD exacerbations in patients with severe COPD. Exacerbation rates, health care resource utilization (HCRU), and costs were compared between roflumilast patients and those receiving other COPD maintenance drugs. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wan, Yin, Sun, Shawn X, Corman, Shelby, Huang, Xingyue, Gao, Xin, Shorr, Andrew F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603715/ https://www.ncbi.nlm.nih.gov/pubmed/26504378 http://dx.doi.org/10.2147/COPD.S80106

Ejemplares similares

Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease
por: Fu, Alex Z, et al.
Publicado: (2015)

Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations
por: Alispahic, Imane Achir, et al.
Publicado: (2020)

Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
por: Kim, Kyung Hoon, et al.
Publicado: (2017)

Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients
por: Liu, Dong-yang, et al.
Publicado: (2018)

Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population
por: Moll, Keran, et al.
Publicado: (2015)

Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease
por: Wagner, Linda Timm, et al.
Publicado: (2005)

Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials
por: Rennard, Stephen I, et al.
Publicado: (2014)

Effectiveness of Roflumilast in Treating Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
por: Naseem, Sumbal, et al.
Publicado: (2022)

Economic Burden of Chronic Obstructive Pulmonary Disease Patients in Malaysia: A Longitudinal Study
por: ur Rehman, Anees, et al.
Publicado: (2020)

Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
por: Hwang, Hyunjung, et al.
Publicado: (2015)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
por: Rennard, Stephen I, et al.
Publicado: (2011)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Economic and Humanistic Burden of Cervical Cancer in the United States: Results from a Nationally Representative Survey
por: Shah, Ruchit, et al.
Publicado: (2020)

Pulmonary Rehabilitation after a Chronic Obstructive Pulmonary Disease Exacerbation: Impact on Readmission Risk in a Real-World Setting
por: Nici, Linda
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
por: Facius, Axel, et al.
Publicado: (2018)

Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome
por: Moore, Kevin, et al.
Publicado: (2020)

The clinical and economic burden of chronic obstructive pulmonary disease in the USA
por: Guarascio, Anthony J, et al.
Publicado: (2013)

The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada
por: Dang-Tan, Tam, et al.
Publicado: (2017)

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
por: Hussain, Arif, et al.
Publicado: (2022)

Antibiotic Retreatment for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
por: Sethi, Sanjay, et al.
Publicado: (2020)

Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting
por: Komura, Moegi, et al.
Publicado: (2023)

Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis
por: Yu, Yanni F., et al.
Publicado: (2016)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
por: Calverley, Peter MA, et al.
Publicado: (2012)

Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)
por: Rodríguez-Nieto, Maria Jesus, et al.
Publicado: (2023)

Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway
por: Xu, Wan, et al.
Publicado: (2021)

The Burden of Nocturnal Symptoms in Patients with Chronic Obstructive Pulmonary Disease: Results of a Real-World Survey in the USA
por: Soler, Xavier, et al.
Publicado: (2022)

A real-world cost-effectiveness analysis of nebulized budesonide and intravenous methylprednisolone in acute exacerbation of chronic obstructive pulmonary disease
por: Gu, Yong-Li, et al.
Publicado: (2022)

Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization
por: Momin, Mohammad A. M., et al.
Publicado: (2021)

The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease
por: Hong, Yoon Duk, et al.
Publicado: (2020)

Efficacy of Roflumilast in Bronchiectasis Patients with Frequent Exacerbations: A Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial
por: Juthong, Siwasak, et al.
Publicado: (2022)

Economic Burden of Heart Failure in Asian Countries Based on Real-world Data
por: Chung, Hyemoon, et al.
Publicado: (2021)

The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis
por: Barer, Yael, et al.
Publicado: (2022)

Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy
por: Antonini, Giovanni, et al.
Publicado: (2023)

Real-world treatment patterns and economic burden of post-cataract macular edema
por: Ahmadyar, Gina, et al.
Publicado: (2023)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease
por: Dragonieri, Silvano, et al.
Publicado: (2016)

The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients
por: Blasi, Francesco, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1t9sd54d41otd0ukt1c4v838cp